Cyril Amarchand Mangaldas advised Rs 9,500 crore acquisition by Advent
Cyril Amarchand Mangaldas advised Rs 9,500 crore acquisition by Advent Cyril Amarchand Mangaldas advised the promoters of Suven Pharmaceuticals Limited (Suven Pharmaceuticals) in relation to the acquisition of Suven Pharmaceuticals by global private equity firm Advent, for an aggregate amount of INR 9,500 crore (approx.) through a share purchase agreement for 51% followed by an open offer...
ToRead the Full Story, Subscribe to
Access the exclusive LEGAL ERAStories,Editorial and Expert Opinion
Cyril Amarchand Mangaldas advised Rs 9,500 crore acquisition by Advent
Cyril Amarchand Mangaldas advised the promoters of Suven Pharmaceuticals Limited (Suven Pharmaceuticals) in relation to the acquisition of Suven Pharmaceuticals by global private equity firm Advent, for an aggregate amount of INR 9,500 crore (approx.) through a share purchase agreement for 51% followed by an open offer for 26%.
The General Corporate and Competition Law Practices Team of Cyril Amarchand Mangaldas acted as the legal counsel for promoters of Suven Pharmaceuticals. The transaction team was led by Shishir Vayttaden, Partner; with support from Reeti Agarwal, Associate; Raksha Raina, Associate; Kashish Mahajan, Associate; Saumya Sharma, Associate; and Tawishi Beria, Associate. Bhargav Joshi, Partner assisted with the due diligence exercise.
The scope of work included undertaking vendor due diligence exercise, carrying out drafting, negotiations, review and finalisation of the share purchase agreement and ancillary agreements.
The Real Estate team was led by Namrata Kolar, Partner (Co-head-Real Estate); with support from Jaideep Kodali, Principal Associate.vPharma and Life Sciences team was led by Biplab Lenin, Partner; with support from Kartik Jain, Senior Associate. Avaantika Kakkar, Partner (Head-Competition Law); advised on the competition law related aspects of the transaction.
As a part of the Transaction, Advent, has agreed to buy out a majority in Suven Pharmaceuticals Limited from our clients. Advent will also make an open offer to acquire 26% shares from public shareholders.
